Commercialization Reports. Bausch Health shall keep Clearside reasonably informed of its, its Affiliates’ and Sublicensees’ Commercialization activities with respect to Products in the Field in the Territory. Without limiting the generality of the foregoing, from time to time, but at least every ​ after the Effective Date, Bausch Health shall provide written updates to Clearside on any Commercialization activities conducted by or on behalf of Bausch Health in the preceding ​ period, covering subject matter at a level of detail reasonably required to enable Clearside to determine Bausch Health’s compliance with its diligence obligations in Section 7.2. Bausch Health shall make available to Clearside such additional information about its Commercialization activities as may be reasonably requested by Clearside from time to time, including pursuant to one or more telephone calls as reasonably requested by Clearside.

Commercialization Reports. At each JCC meeting, # Stoke shall provide the JCC a summary of the progress and results of Commercialization activities for any [[Unknown Identifier]] Co-Co Product for which Stoke is the Lead Commercialization Party or otherwise responsible for, # Acadia shall provide the JCC a summary of the progress and results of Commercialization activities for any [[Unknown Identifier]] Co-Co Product for which Acadia is the Lead Commercialization [[Person A:Person]] Party or otherwise responsible for. Without limiting the foregoing, at each meeting of the JCC, each Party shall provide to the JCC a summary of sales forecasts, sales performance reports, and other information for such [[Unknown Identifier]] Co-Co Product, as applicable.

Commercialization Reports. No later than ​ following the end of each Calendar Year during which Licensee is conducting commercialization activities hereunder, Licensee shall provide [[AstraZeneca:Organization]] with a written report describing such commercialization activities it has performed, or caused to be performed, since the preceding report (or the Effective Date, with respect to the first report) and a description of the future activities it expects to initiate during the following ​ period. Each such report shall contain sufficient detail to reasonably enable [[AstraZeneca:Organization]] to assess Licensee’s compliance with its obligations set forth in Section 3.6.2. [[AstraZeneca:Organization]] acknowledges and agrees that any forward looking activities and information in any such report are to be based on Licensee’s good faith plans, objectives and expectations, may not be completed or achieved, and will be subject to change.

Commercialization Reports. Zai will update the JSC at each regularly scheduled JSC meeting regarding Zai’s Commercialization activities with respect to the Licensed Products in the Territory. Each such update will be in a form to be agreed by the JSC and will summarize Zai’s, its Affiliates’ and Sublicensees’ significant Commercialization activities with respect to the Licensed Products in the Territory, covering subject matter at a level of detail reasonably required by NVCR and sufficient to enable NVCR to determine Zai’s compliance with its diligence obligations pursuant to Section 8.1. In addition, Zai will make available to NVCR such additional information about its Commercialization activities as may be reasonably requested by NVCR from time to time. For clarity, Zai will not be required to include information in its updates and reports under this Section 8.3 that it does not otherwise create for its own internal purposes. All updates and reports generated pursuant to this Section 8.3 shall be the Confidential Information of Zai.

Commercialization Reports. Abbott shall keep the JSC regularly informed of the progress of its efforts to Commercialize Products in the Field and in the Territory. Without limiting the generality of the foregoing, Abbott shall provide Enanta with semi-annual written updates to each Marketing and Sales Plan, which shall # summarize Abbott’s efforts to Commercialize Products, # identify the Regulatory Filings and Drug Approval Applications with respect to Candidates that Abbott or any of its Affiliates or Sublicensees have filed in the prior twelve (12) month period or reasonably expect to make in the following twelve (12) month period, # identify the Regulatory Approvals with respect to Products that Abbott or any of its Affiliates or Sublicensees have obtained in the prior twelve (12) month period or reasonably expect to obtain in the following twelve (12) month period, and # summarize all clinical and other data generated by Abbott with respect to Products. In addition, Abbott shall provide such additional information that it has in its possession as may be reasonably requested from time to time by the JSC regarding the Commercialization of any Product.

Commercialization Reports. Ji Xing shall keep [[Cytokinetics:Organization]] informed of its, its Affiliates’ and sublicensees’ Commercialization activities with respect to the Product. Without limiting the foregoing, Ji Xing shall update the JCC at each regularly scheduled JCC meeting regarding the Commercialization activities with respect to the Product in the Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Ji Xing’s, its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Product in the Territory, covering subject matter at a level of detail reasonably required by [[Cytokinetics:Organization]] and sufficient to enable [[Cytokinetics:Organization]] to determine Ji Xing’s compliance with its diligence obligations pursuant to Section 8.2. In addition, Ji Xing shall make available to [[Cytokinetics:Organization]] such additional information about its Commercialization activities as may be reasonably requested by [[Cytokinetics:Organization]] from time to time. Ji Xing shall ​.

Commercialization Reports. On a semi-annual basis after Marketing Approval of any Licensed Product, Janssen shall provide to the JSC a high-level summary report of its Commercialization launch status, activities, and performance with respect to each Licensed Product since the previous JSC summary. At each JSC meeting, Janssen shall provide additional information as reasonably requested by Fate’s JSC representatives with respect to the Commercialization activities summarized in such report or otherwise conducted or anticipated to be conducted for each Licensed Product.

Commercialization Reports. Acadia shall provide to Stoke an annual report on its Commercialization of the Licensed Products in the Territory. Each such report shall summarize Acadia’s and its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Licensed Products throughout the Territory and will be at a level of detail sufficient to enable Stoke to determine Acadia’s compliance with its diligence obligations in [Section 5.5(b)]. Without limiting the foregoing, Acadia shall timely respond to Stoke’s representatives’ reasonable questions or requests for additional information relating to such Commercialization activities.

Commercialization Reports. Ji Xing shall keep [[Cytokinetics:Organization]] informed of its, its Affiliates’ and sublicensees’ Commercialization activities with respect to the Product. Without limiting the foregoing, Ji Xing shall update the JCC at each regularly scheduled JCC meeting regarding the Commercialization activities with respect to the Product in the Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Ji Xing’s, its Affiliates’ and sublicensees’ significant Commercialization activities with respect to the Product in the Territory, covering subject matter at a level of detail reasonably required by [[Cytokinetics:Organization]] and sufficient to enable [[Cytokinetics:Organization]] to determine Ji Xing’s compliance with its diligence obligations pursuant to Section 8.2. In addition, Ji Xing shall make available to [[Cytokinetics:Organization]] such additional information about its Commercialization activities as may be reasonably requested by [[Cytokinetics:Organization]] from time to time. Ji Xing shall ​.

Commercialization Reports. Beginning ​ (​) calendar quarters prior to the anticipated First Commercial Sale of a Licensed Product in the Field in the Territory, and every calendar quarter thereafter, Licensee shall report to Bioeq # the Commercialization activities (or preparations for First Commercial Sale, as applicable) performed in relation to the Licensed Products in the preceding four (4) calendar quarters, # the planned Commercialization activities (or preparations for First Commercial Sale, as applicable) in relation to the Licensed Products planned for the four (4) calendar quarters following such quarter, and # any significant changes in the market or of the competitive landscape. In addition, Licensee shall promptly respond to Bioeq’s reasonable questions or requests for information relating to Licensee’s and its Affiliates’ Commercialization activities with respect to the Licensed Products in the Field in the Territory, including activities performed to prepare for the First Commercial Sale.